Skip to Content
Merck
CN
  • Outcome of transplantation for acute lymphoblastic leukemia in children with Down syndrome.

Outcome of transplantation for acute lymphoblastic leukemia in children with Down syndrome.

Pediatric blood & cancer (2014-01-07)
Johann K Hitzler, Wensheng He, John Doyle, Mitchell Cairo, Bruce M Camitta, Ka Wah Chan, Miguel A Diaz Perez, Christopher Fraser, Thomas G Gross, John T Horan, Alana A Kennedy-Nasser, Carrie Kitko, Joanne Kurtzberg, Leslie Lehmann, Tracey O'Brien, Michael A Pulsipher, Franklin O Smith, Mei-Jie Zhang, Mary Eapen, Paul A Carpenter
ABSTRACT

We report on 27 patients with Down syndrome (DS) and acute lymphoblastic leukemia (ALL) who received allogeneic hematopoietic cell transplantation (HCT) between 2000 and 2009. Seventy-eight percent of patients received myeloablative conditioning and 52% underwent transplantation in second remission. Disease-free survival (DFS) was 24% at a median of 3 years. Post-transplant leukemic relapse was more frequent than expected for children with DS-ALL (54%) than for non-DS ALL. These data suggest leukemic relapse rather than transplant toxicity is the most important cause of treatment failure. Advancements in leukemia control are especially needed for improvement in HCT outcomes for DS-ALL.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
FK-506 monohydrate, ≥98% (HPLC)
USP
Tacrolimus, United States Pharmacopeia (USP) Reference Standard
Supelco
Cyclosporin A solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®